blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1784179

EP1784179 - COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  29.03.2013
Database last updated on 03.01.2025
Most recent event   Tooltip29.03.2013Application deemed to be withdrawnpublished on 01.05.2013  [2013/18]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[N/P]
Former [2012/33]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway NJ 07065-0907 / US
Former [2012/32]For all designated states
Schering Corporation
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Former [2010/10]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Former [2007/20]For all designated states
Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
Inventor(s)01 / SIMON, Thomas, J.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
02 / REICIN, Alise, S.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
03 / HUNT, Richard
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
 [2007/20]
Representative(s)Man, Jocelyn, et al
Merck & Co., Inc.
European Patent Department
Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire, EN11 9BU / GB
[N/P]
Former [2007/20]Man, Jocelyn, et al
Merck & Co., Inc. European Patent Department Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon
Hertfordshire, EN11 9BU / GB
Application number, filing date05858077.019.08.2005
[2007/20]
WO2005US29625
Priority number, dateUS20040604124P24.08.2004         Original published format: US 604124 P
[2007/20]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006137839
Date:28.12.2006
Language:EN
[2006/52]
Type: A2 Application without search report 
No.:EP1784179
Date:16.05.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 28.12.2006 takes the place of the publication of the European patent application.
[2007/20]
Search report(s)International search report - published on:US25.10.2007
(Supplementary) European search report - dispatched on:EP01.03.2010
ClassificationIPC:A61K31/50, A61K31/34
[2007/51]
CPC:
A61K45/06 (EP,US); A61K31/4152 (EP,US); A61K31/4439 (EP,US);
A61P19/00 (EP); A61P9/00 (EP)
C-Set:
A61K31/4152, A61K2300/00 (EP,US);
A61K31/4439, A61K2300/00 (US,EP)
Former IPC [2007/20]A61K31/4152
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/20]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON CYCLOOXYGENASE-2-VERMITTELTEN KRANKHEITEN ODER ZUSTÄNDEN BEI PATIENTEN MIT RISIKO AUF THROMBOTISCHE KARDIOVASKULÄRE EREIGNISSE[2007/20]
English:COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS[2007/20]
French:PLURITHERAPIE POUR TRAITER DES MALADIES OU DES TROUBLES MEDIES PAR LA CYCLO-OXYGENASE 2 CHEZ DES PATIENTS PRESENTANT UN RISQUE D'EVENEMENT CARDIO-VASCULAIRE THROMBOTIQUE[2007/20]
Entry into regional phase26.03.2007National basic fee paid 
26.03.2007Search fee paid 
25.04.2008Designation fee(s) paid 
25.04.2008Examination fee paid 
Examination procedure07.02.2007Amendment by applicant (claims and/or description)
25.04.2008Examination requested  [2008/24]
23.04.2010Despatch of a communication from the examining division (Time limit: M04)
01.09.2010Reply to a communication from the examining division
17.09.2010Despatch of a communication from the examining division (Time limit: M06)
28.03.2011Reply to a communication from the examining division
24.06.2011Despatch of a communication from the examining division (Time limit: M06)
05.04.2012Reply to a communication from the examining division
23.04.2012Despatch of a communication from the examining division (Time limit: M06)
06.11.2012Application deemed to be withdrawn, date of legal effect  [2013/18]
11.12.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2013/18]
Divisional application(s)EP12166176.3  / EP2494992
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.04.2010
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
05.04.2012Request for further processing filed
05.04.2012Full payment received (date of receipt of payment)
Request granted
20.04.2012Decision despatched
Fees paidRenewal fee
03.08.2007Renewal fee patent year 03
27.03.2008Renewal fee patent year 04
07.08.2009Renewal fee patent year 05
06.08.2010Renewal fee patent year 06
08.08.2011Renewal fee patent year 07
08.08.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO02098352  (POZEN INC [US]) [X] 1-11 * examples 5-8 * * claims 1-8 * * page 9, line 17 - page 10, line 18 * [Y] 1-19;
 [E]WO2005076987  (SANTARUS INC [US], et al) [E] 1-3,6,11-13,17 * page 29 * * tables 6.E, 8.A, 8.D ** page 88, line 1 - line 9 *;
 [XY]  - "AGA abstracts W1190-W1748", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, (20040401), vol. 126, no. 4, ISSN 0016-5085, pages A586 - A659, XP022471379 [X] 11 * paragraph [W1344] * [Y] 1-19

DOI:   http://dx.doi.org/10.1016/S0016-5085(04)80015-5
 [X]  - HASSAN-ALIN M ET AL, "Lack of drug-drug interaction between esomeprazole and rofecoxib in healthy subjects", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200307), Database accession no. PREV200600079181, XP002568490 [X] 11 * abstract *
International search[X]US2003069255  (PLACHETKA JOHN R [US]);
 [Y]US6245797  (WINOKUR MELVIN [US]);
 [Y]US6323188  (WEISSMAN DONALD L [US])
ExaminationUS6136804
 US2003143271
 US2004110747
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.